As of September 27, 2026, OpenEvidence has not filed a registration statement, and no Form S-1 appears on SEC EDGAR, which covers only US filings. Crunchbase News reported on September 2, 2026 that OpenEvidence was one of eight startups it judged to have a 'probable' chance of an IPO within six months, citing CEO Daniel Nadler's view that foundation-model companies such as OpenAI and Anthropic need to go public before application-layer companies like OpenEvidence can follow. On September 24, 2026, Business Insider reported that OpenEvidence had raised $250 million from hospital systems and Andreessen Horowitz at a $15 billion valuation, up from the $12 billion it reached in a January 2026 round. Separately, on September 22, 2026, Reuters reported that Anthropic and OpenEvidence had announced a partnership to expand AI-powered clinical decision support to physicians in dozens of low- and middle-income countries. None of this reporting is an IPO filing or a confirmed date. Track SEC EDGAR and OpenEvidence's own statements directly, not secondary chatter.
segmara.com publishes educational private-market context and can route limited interest into account-based private follow-up. Public pages do not create an offer, allocation, payment instruction, investment advice, or issuer-affiliated workflow.
Key points
A 'probable' rating, not a filing
Crunchbase News reported on September 2, 2026 that OpenEvidence was one of eight startups it judged to have a 'probable' chance of going public within six months. The assessment was tied to comments from CEO Daniel Nadler, whom Crunchbase said believes foundation-model companies such as OpenAI and Anthropic have to complete their own public listings before application-layer companies like OpenEvidence follow onto the market.
That is an analyst's forward-looking read, not a registration statement. As of September 27, 2026, no Form S-1 or F-1 for OpenEvidence appears on SEC EDGAR, which covers only US filings, and OpenEvidence has not announced a listing date.
The valuation has moved fast
Business Insider reported on September 24, 2026 that OpenEvidence raised $250 million from hospital systems and Andreessen Horowitz at a valuation of $15 billion. That is up from the $12 billion valuation it reached in a January 2026 round, according to the same report.
Neither figure is tied to a public offering price; both describe private funding rounds.
A partnership with one of the foundation-model companies it's waiting on
On September 22, 2026, Reuters reported that Anthropic and OpenEvidence had announced a partnership to expand AI-powered clinical decision support to physicians in dozens of low- and middle-income countries.
The deal links OpenEvidence to Anthropic, one of the foundation-model companies that CEO Daniel Nadler said, per Crunchbase News, needs to go public before application-layer companies like OpenEvidence can follow. The partnership itself is a product and distribution deal, not an IPO step.
AI-ready data summary
A structured extraction layer for this article: catalogue numbers, price context, chart values, and route-specific facts that search and AI systems can read directly from the page.
Metric
Value
Context
Canonical route
/blog/when-will-openevidence-ipo
Stable URL path for AI and search extraction.
Article title
When Will OpenEvidence IPO? A $15 Billion Valuation, Still No Filing
Main page topic.
Attached public sources
3
Number of citation links rendered at the bottom of the article.
Segmara listed companies
51
Live private-company listings in the public catalogue.
Priced listings
37
Catalogue listings with visible indicative or direct marks.
Request-quote listings
14
Catalogue listings where a public price is intentionally not invented.
Data fingerprint chart
Catalogue breadth100%
51 public listings
Visible pricing coverage72%
37 of 51 listings show a mark
Source depth58%
3 source links
Stage
Timing
Price / valuation signal
Interpretation
Chart metric
Score
Interpretation
Catalogue breadth
100 / 100
51 public listings
Visible pricing coverage
72 / 100
37 of 51 listings show a mark
Source depth
58 / 100
3 source links
Analytical lens
Search intent
The search behind 'When Will OpenEvidence IPO? A $15 Billion Valuation, Still No Filing' is an access-intent query. People want to know where they can start interest in OpenEvidence private-market exposure without needing a private equity relationship, fund connection, or insider network.
Access path
segmara.com turns that search into a simple path: browse the listing, create an account, choose the company, and start the private-share inquiry. Final pricing and availability still depend on the route, but the starting point is public and straightforward.
Segmara role
Segmara works as a private-market access layer for interested visitors. The site helps visitors discover private markets categories that were previously hard to research and moves them into an account-based inquiry in a few steps.
Private-share path map
From gatekept to accessible
BrowseRetail investor finds a private-company listing.
AccountBuyer creates one Segmara account.
RequestBuyer starts the private-share purchase request.
CloseAvailability, price, approvals, and final terms are handled privately.
Access-friction chart
Illustrative map of where the old private-market process was hardest and where Segmara makes the starting point easier.
Old-market frictionPrivate networks and institutional access
Segmara discoveryPublic listings retail buyers can browse
Account workflowOne account to start the purchase request
Private closeFinal terms handled after buyer interest
How private-share access starts on Segmara
No Form S-1 or F-1 for OpenEvidence appears on SEC EDGAR as of September 27, 2026; Crunchbase News reported on September 2, 2026 that the company was among eight startups it rated a 'probable' candidate for an IPO within six months, citing CEO Daniel Nadler's view that foundation-model makers such as OpenAI and Anthropic must list first.
Business Insider reported on September 24, 2026 that OpenEvidence raised $250 million from hospital systems and Andreessen Horowitz, lifting its valuation to $15 billion from the $12 billion it reached in a January 2026 round.
Reuters reported on September 22, 2026 that Anthropic and OpenEvidence had partnered to expand AI-powered clinical decision support to physicians in dozens of low- and middle-income countries.
Risk notes
Rumor risk: unofficial dates, valuations, or funding details circulating on social media or forums are frequently wrong or outdated and should not be treated as confirmation of anything.
Illiquidity risk: any private-market interest, indicative marks, or pre-IPO share arrangements in a company that has not listed can be difficult to exit and may not reflect a tradable price.
Timing risk: a company can pause, restart, or abandon IPO preparation at any stage, including after a confidential or public filing, so no step before pricing guarantees a listing.
Get the alert the day OpenEvidence files or prices
Free: every article, the IPO calendar and the weekly IPOs page. Pro: same-day filing alerts and the weekly brief on all 99 companies, with a 7-day free trial, then $15 a month. Research only, no share sales.
Can retail investors track private-company shares on Segmara?
Yes. Visitors can start with the free OpenEvidence tracker using email only, then decide whether a private follow-up makes sense. Availability, eligibility, pricing, allocation, transfer approval, documents, and final terms can still vary by route.
Why was this market historically hard for retail investors to reach?
Private-company share access has often moved through private equity firms, venture funds, insiders, institutions, and relationship-driven secondary networks. Segmara makes the starting point simpler: visitors can follow named private-company interest before any account, document upload, or payment step.
What is the easiest next step?
Open the free OpenEvidence tracker first. It is email-only and keeps the public step narrow while final availability, pricing, eligibility, and terms are handled only through private follow-up.
Has OpenEvidence confirmed an IPO date?
No. As of September 27, 2026, no S-1 or F-1 has been filed on SEC EDGAR. Crunchbase News rated OpenEvidence a 'probable' IPO candidate within six months on September 2, 2026, but that is an analyst assessment, not a company-confirmed date.
What is OpenEvidence worth?
Business Insider reported on September 24, 2026 that OpenEvidence raised $250 million from hospital systems and Andreessen Horowitz at a $15 billion valuation, up from the $12 billion it reached in a January 2026 round.
Why does OpenEvidence's IPO timing depend on OpenAI and Anthropic?
Crunchbase News reported on September 2, 2026 that CEO Daniel Nadler believes foundation-model companies such as OpenAI and Anthropic need to go public before application-layer companies like OpenEvidence can follow, part of why Crunchbase called an OpenEvidence IPO 'probable' within six months rather than confirmed.
Can I buy OpenEvidence shares before the IPO?
Not through a public exchange. OpenEvidence is a private company, and Segmara does not sell, broker, or arrange purchases of OpenEvidence shares.
Next step
Track private-market prices free.
If this article helped explain OpenEvidence, start with the free tracker: indicative pre-IPO marks by email. No card, no documents, no brokerage account, and no allocation promise.
When a full account makes sense, Segmara can route limited interest into an account-based private follow-up. Availability, pricing, eligibility, allocation, transfer approval, liquidity, and final terms can vary by company and route.